ALLO · Allogene Therapeutics, Inc.
$2.05
+0.07 (+3.54%)
At close · Aug 14
Market Cap
$708.26M
Shares
345.49M
Allogene Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Allogene Therapeutics, Inc. (ALLO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼44.9%
$27,000
−$84.24M
'22 Q3
22-11-02
▼100%
$26,000
−$97.28M
'22 Q4
23-02-28
▼23.1%
$30,000
−$99.97M
'23 Q1
23-05-03
▼65.6%
$22,000
−$79.23M
'23 Q2
23-08-02
▼18.5%
$22,000
−$62.29M
'23 Q3
23-11-02
▼19.2%
$21,000
−$85.78M
'23 Q4
24-03-14
▼26.7%
$22,000
−$65.00M
'24 Q1
24-05-13
▼100%
$
−$66.36M
'24 Q2
24-08-07
▼100%
$
−$66.29M
'24 Q3
24-12-02
▼100%
$
−$59.94M
'24 Q4
25-03-13
▼100%
$
−$59.73M
'25 Q1
25-05-13
·
$
−$50.94M
'25 Q2
25-08-13
·
$
−$41.40M
'25 Q3
25-11-06
·
$
−$38.81M
'25 Q4
26-03-12
LATEST
·
$4.64M
−$42.68M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
The Allogene Therapeutics Second Quarter 2026 Conference Call
Revenue
$4.64M
Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference, New York
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-13
Allogene Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
Allo-329 autoimmune program
Semicel (cema-cel) Alpha-3 MRD interim analysis
MRD as treatment-decision paradigm / Natera Clarity assay
Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Allogene Therapeutics, Inc. Q4 FY2025 Earnings Call
Positive tone
ALPHA-3 trial in LBCL
ALLO-329 in autoimmune disease
Data readouts and proof points
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Allogene Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
ALLO-329 in autoimmune disease (Resolution study)
Allogeneic platform scalability vs autologous
ALPHA3 trial of cema-cel in first-line LBCL consolidation
Revenue
$
Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allogene Therapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone
ALPHA3 / cema-cel trial design change
ALLO-329 in autoimmune disease / RESOLUTION study
Allogeneic platform differentiation and durability
Revenue
$
Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Allogene Therapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone
ALPHA3 pivotal trial (cema-cel, 1L LBCL)
ALLO-329 RESOLUTION trial in autoimmune disease
ALLO-316 TRAVERSE trial in renal cell carcinoma
Revenue
$
▼ 100% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Allogene Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
ALLO-501A pivotal ALPHA3 trial in LBCL
ALLO-329 autoimmune expansion
Upcoming catalysts and trial milestones
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Allogene Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
ALLO-329 dual CAR for autoimmune disease
ALLO-316 in advanced renal cell carcinoma
ALPHA3 pivotal trial for cema-cel in first-line LBCL
Revenue
$
▼ 100% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Allogene Therapeutics, Inc. Q2 FY2024 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Allogene Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Cema-cel / ALPHA3 pivotal trial in 1L LBCL
ALLO-329 autoimmune program with Dagger
ALLO-316 / TRAVERSE in renal cell carcinoma
Revenue
$22,000
▼ 26.7% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Allogene Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
ALLO-329 autoimmune disease
CLL / ALPHA2 cohort
Corporate pivot and strategy
Revenue
$21,000*
▼ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Allogene Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$22,000
▼ 18.5% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Allogene Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$22,000
▼ 65.6% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Allogene Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$30,000
▼ 23.1% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Allogene Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$26,000*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Allogene Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$27,000
▼ 44.9% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Allogene Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$64,000
▲ 45.5% YoY Diluted EPS
$-0.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Allogene Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$39,000
▼ 99.9% YoY Diluted EPS
$-0.56
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Allogene Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$75.65M*
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Allogene Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$49,000
Diluted EPS
$-0.57
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Allogene Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$44,000
Diluted EPS
$-0.53
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Allogene Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$38.34M
Diluted EPS
$-0.25
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Allogene Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Allogene Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$
Diluted EPS
$-0.52
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Allogene Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$
Diluted EPS
$-0.53
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Allogene Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Allogene Therapeutics, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1737287
CUSIP
019770106
13F (30d)
203 filings
200 filers
Visit website
Investor relations